Overview: Reveals latest discoveries related to the molecular mechanisms of proteasome inhibitor resistance.Discusses proteasome inhibitor resistance in multiple contexts, including multiple myeloma, leukemia, .The book explores cutting-edge strategies to overcome proteasome inhibitor resistance, including the second generation 20S proteasome inhibitors, novel combinational therapies, and new targets in the ubiquitin-proteasome pathway (e.g., ubiquitin E3 ligases, deubiquitinases, 19S proteasomal ATPases, histone deacetylases, oxidative stress and proteotoxic stress pathways and pharmacogenomi
|